RXRX
NASDAQ · Biotechnology
Recursion Pharmaceuticals-A
$3.27
-0.16 (-4.66%)
Performance
1D
—
1W
—
1M
—
3M
-17.84%
6M
-30.57%
1Y
-29.53%
YTD
-22.14%
Open$3.37
Previous Close$3.43
Day High$3.52
Day Low$3.26
52W High$7.18
52W Low$2.80
Volume—
Avg Volume12.05M
Market Cap1.73B
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$4.31
Below
SMA 200
$4.89
Below
RSI (14)
34.7
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Buy
14 analysts
Price Target
+783.8% upside
Current
$3.27
$3.27
Target
$28.90
$28.90
$21.05
$28.90 avg
$39.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 88.17M | 71.51M | 309.68M |
| Net Income | -761,283,693 | -555,681,527 | -18,426,824 |
| Profit Margin | -863.4% | -820.2% | -6.0% |
| EBITDA | -726,785,549 | -559,972,645 | -21,116,374 |
| Free Cash Flow | — | — | -13,211,156 |
| Rev Growth | +23.3% | +23.3% | +0.8% |
| Debt/Equity | 0.02 | 0.02 | 0.47 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |